Elan leans on ISEQ losers
Shares at pharmaceutical company Elan tumbled 6% today after sales of its multiple sclerosis drug Tysabri came below expectations.
The stock led ISEQ-listed fallers with an overall decline of 92.61points at 9608.8.
Try from €1.25 / week
SUBSCRIBEShares at pharmaceutical company Elan tumbled 6% today after sales of its multiple sclerosis drug Tysabri came below expectations.
The stock led ISEQ-listed fallers with an overall decline of 92.61points at 9608.8.
CONNECT WITH US TODAY
Be the first to know the latest news and updates
Newsletter
News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.
Push Notifications
By clicking on sign up you will be the first to know about a selection of business content on this browser. Please note if you are unable to sign up via your mobile web browser, download and sign up for mobile push notifications via our FREE news app.
Sign UpYou have accepted push notifications for this content. If you would like to manage your push notification preferences, you can do so here.
Newsletter
News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.
Newsletter
Keep up with stories of the day with our lunchtime news wrap and important breaking news alerts.
Tuesday, September 30, 2025 - 5:00 PM
Tuesday, September 30, 2025 - 2:00 PM
Tuesday, September 30, 2025 - 11:00 AM
© Examiner Echo Group Limited